Clinical Trial

A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is testing a new medicine that might help treat people with type 2 diabetes. The purpose of the study is to see if the new study medicine is safe and how well is tolerated by the body. There will be two groups of participants in this study: healthy participants and participants with type 2 diabetes. Participant will either get study medicine (NNC1679-0001) or placebo (a treatment that has no active medicine in it). NNC1679-0001 is a new experimental medicine that doctors cannot prescribe yet. Which treatment the participant gets is decided by chance. Participant will get one dose which will be injected into the area around abdomen (belly) by the medical staff.
Protocol Amendment History 2 changes
notable Enrollment reduced: 80 -> 58 participants 2026-06-23
critical Recruitment opened 2026-05-20
Trial Details
NCT Number NCT07570992
Lead Sponsor Novo Nordisk A/S
Conditions Healthy Volunteers, Diabetes Mellitus, Type 2
Enrollment 58 participants
Start Date 2026-05-04
Primary Completion 2028-06-25 (estimated)
Study Completion 2028-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-22